Results 1 to 10 of about 16,874 (230)

TMAO as a potential biomarker and therapeutic target for chronic kidney disease: A review

Frontiers in Pharmacology, 2022
The gut microbiota and its metabolites have become a hotspot of recent research. Trimethylamine N-oxide (TMAO) metabolized by the gut microbiota is closely related to many diseases such as cardiovascular disease, chronic kidney disease, type 2 diabetes ...
Ye Zixin, Ye Zixin, Ye Zixin, Ye Zixin, Chen Lulu, Chen Lulu, Zeng Xiangchang, Zeng Xiangchang, Zeng Xiangchang, Zeng Xiangchang, Fang Qing, Zheng Binjie, Zheng Binjie, Zheng Binjie, Zheng Binjie, Luo Chunyang, Rao Tai, Rao Tai, Rao Tai, Rao Tai, Ouyang Dongsheng, Ouyang Dongsheng, Ouyang Dongsheng, Ouyang Dongsheng, Ouyang Dongsheng   +24 more
exaly   +4 more sources

Gut Microbiota-Derived TMAO: A Causal Factor Promoting Atherosclerotic Cardiovascular Disease?

International Journal of Molecular Sciences, 2023
Trimethylamine-N-oxide (TMAO) is the main diet-induced metabolite produced by the gut microbiota, and it is mainly eliminated through renal excretion. TMAO has been correlated with an increased risk of atherosclerotic cardiovascular disease (ASCVD) and ...
Marina Canyelles, Noemi Rotllan Vila, Mireia Tondo   +2 more
exaly   +2 more sources

Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways

JCI Insight, 2023
We determined whether gut microbiota-produced trimethylamine (TMA) is oxidized into trimethylamine N-oxide (TMAO) in nonliver tissues and whether TMAO promotes inflammation via trained immunity (TI).
Fatma Saaoud, Lu Liu, Keman Xu, Ramon Cueto, Ying Shao, Yifan Lu, Yu Sun, Nathaniel W. Snyder, Sheng Wu, Ling Yang, Yan Zhou, David L. Williams, Chuanfu Li, Laisel Martinez, Roberto I. Vazquez-Padron, Huaqing Zhao, Xiaohua Jiang, Hong Wang, Xiaofeng Yang   +18 more
doaj   +2 more sources

Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota

Signal Transduction and Targeted Therapy, 2022
Trimethylamine-N-oxide (TMAO) derived from the gut microbiota is an atherogenic metabolite. This study investigates whether or not berberine (BBR) could reduce TMAO production in the gut microbiota and treat atherosclerosis.
Qian Tong, Hang Yu, Jian-Dong Jiang
exaly   +2 more sources

TMAO Promotes NLRP3 Inflammasome Activation of Microglia Aggravating Neurological Injury in Ischemic Stroke Through FTO/IGF2BP2

Journal of Inflammation Research, 2023
Pengxin Ge,1,* Huijie Duan,2,* Chunrong Tao,3,* Sensen Niu,4 Yiran Hu,5 Rui Duan,6 Aizong Shen,7 Yancai Sun,1 Wen Sun3 1Department of Pharmacy, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences
Ge P, Duan H, Tao C, Niu S, Hu Y, Duan R, Shen A, Sun Y, Sun W   +8 more
doaj   +2 more sources

Gut-Derived Metabolite, Trimethylamine-N-oxide (TMAO) in Cardio-Metabolic Diseases: Detection, Mechanism, and Potential Therapeutics

Pharmaceuticals, 2023
Trimethylamine N-oxide (TMAO) is a biologically active gut microbiome-derived dietary metabolite. Recent studies have shown that high circulating plasma TMAO levels are closely associated with diseases such as atherosclerosis and hypertension, and ...
Meyammai Shanmugham, Sophie Bellanger, Chen H Leo   +2 more
exaly   +2 more sources

Establishment of a mouse model of TMAO‐induced cardiac injury and application of MICT intervention [PDF]

Animal Models and Experimental Medicine
Background This study aims to explore the establishment of an animal model of cardiac injury induced by trimethylamine‐N‐oxide (TMAO), a metabolite secreted by gut microorganisms, and to investigate its application in moderate‐intensity continuous ...
Zhongping Xie, Hong Zou, Lijing Gong, Minghui Lin, Caihua Huang   +4 more
doaj   +2 more sources

The Fibrotic Effects of TMAO on Human Renal Fibroblasts Is Mediated by NLRP3, Caspase-1 and the PERK/Akt/mTOR Pathway

International Journal of Molecular Sciences, 2021
Trimethylamine N-oxide (TMAO), a product of gut microbiota metabolism, has previously been shown to be implicated in chronic kidney disease. A high TMAO-containing diet has been found to cause tubulointerstitial renal fibrosis in mice.
Ashok Kumar Kumawat
exaly   +2 more sources

The associations between TMAO-related metabolites and blood lipids and the potential impact of rosuvastatin therapy

Lipids in Health and Disease, 2022
Background Trimethylamine N-oxide (TMAO)-related metabolites are associated with the pathogenesis of atherosclerotic cardiovascular disease (ASCVD) and are known to disrupt lipid metabolism.
Xiaowei Xiong, Jian Zhou, Qiang Fu, Xiaowei Xu, Shaobin Wei, Shenghua Yang, Buxing Chen   +6 more
doaj   +2 more sources

Gut Metabolite TMAO Induces Synaptic Plasticity Deficits by Promoting Endoplasmic Reticulum Stress

Frontiers in Molecular Neuroscience, 2020
Dysbiosis of gut microbiota is strongly associated with metabolic diseases including diabetes mellitus, obesity, and cardiovascular disease. Recent studies indicate that Trimethylamine N-oxide (TMAO), a gut microbe-dependent metabolite is implicated in ...
Manoj Govindarajulu, Jenna Bloemer, Sindhu Ramesh   +2 more
exaly   +3 more sources